verekitug
Upstream Bio Details 56% Reduction in Asthma Exacerbations
Upstream Bio Inc. (Nasdaq: UPB) presented detailed Phase 2 results for verekitug in severe asthma at the European Respiratory Society Congress on September 8, 2026. The company reported that 100 mg of verekitug administered every 12 weeks reduced the annualized asthma exacerbation rate by 56% compared with placebo, meeting the trial’s primary endpoint with a…
